ISYNA1, inositol-3-phosphate synthase 1, 51477

N. diseases: 168; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis
0.030 AlteredExpression disease BEFREE To understand better the poor resistance to infections in the CF lung, the expression of the iNOS gene was investigated in explanted lungs from patients with cystic fibrosis (n = 13), bronchiectasis (n = 3), emphysema (n = 14), and in normal lungs (n = 8). 9614386 1998
Diabetes Mellitus, Non-Insulin-Dependent
0.030 Biomarker disease BEFREE Yet, iPS generation from patients with type 2 diabetes (T2D) has not been demonstrated. 22308265 2012
Diabetes Mellitus, Non-Insulin-Dependent
0.030 AlteredExpression disease BEFREE This pilot study analyzed whether a 3-month endurance training can affect iNOS protein and NO metabolite levels in the vastus lateralis muscle of insulin-independent T2DM men, thereby affecting the patients` glycemic control. 27782779 2017
Diabetes Mellitus, Non-Insulin-Dependent
0.030 GeneticVariation disease BEFREE We previously reported the association of the Z-2 allele of the promoter dinucleotide repeat in the Aldose reductase (ALR2) gene, the (CCTTT)₁₅ allele in the promoter of inductible nitric oxide synthase (iNOS) gene, and the (GT)₁₃ promoter polymorphism in the tumor necrosis factor β (TNFB) gene with an increased risk for diabetic retinopathy (DR), and the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene and the (GT)₉ allele of the TNFB gene with low-risk for DR in a hospital-based self-reported type 2 diabetes mellitus (T2DM) patients. 21067489 2010
CUI: C0024530
Disease: Malaria
Malaria
0.030 GeneticVariation disease BEFREE The single nucleotide substitution, -954G-->C, in the iNOS promoter was rare in Thai patients with malaria. 12195390 2002
CUI: C0024530
Disease: Malaria
Malaria
0.030 GeneticVariation disease BEFREE Here, we experimentally elucidate that iNOS promoter polymorphisms are associated with risk of malaria; employing mutation specific genotyping, functional interplay using western blot and RT-PCR, quantitative estimation of NO, total antioxidant content (TAC) and reactive oxygen species (ROS). 29268202 2018
CUI: C0024530
Disease: Malaria
Malaria
0.030 GeneticVariation disease BEFREE These findings suggest that iNOS promoter haplotypes rather than single nucleotide polymorphisms are associated with malaria in Ghanaian children. 15482399 2004
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.030 AlteredExpression disease BEFREE Quantitation of iNOS transcripts and iNOS enzyme activity in non-cancerous mucosa of gastric cancer patients revealed a significant increase in iNOS transcripts and iNOS activity only in the mucosa of patients with stomach cancer of the intestinal type but not in the diffuse type. 14760971 2003
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.030 GeneticVariation disease BEFREE A CT or TT polymorphism at position 150 in the iNOS gene significantly increases the risk of GC and may be a marker for GC susceptibility. 23002365 2012
CUI: C0024623
Disease: Malignant neoplasm of stomach
Malignant neoplasm of stomach
0.030 GeneticVariation disease BEFREE Rafiei et al recently described an association between the presence of the C150T polymorphism of the inducible nitric oxide synthase (iNOS) gene and Helicobacter pylori (H. pylori) induced gastric cancer. 23372371 2013
CUI: C0025202
Disease: melanoma
melanoma
0.030 AlteredExpression disease BEFREE The Cd contents, expression of melanoma-associated differentiation gene 5 (MDA5) and its downstream signaling molecules (interferon promoter-stimulating factor 1 (IPS-1), transcription factors interferon regulatory factor 3 (IRF3), and nuclear factor kappa-light chain-enhancer of activated B cells (NF-κB)), the content of cytokines (interleukin 1β (IL-1β), interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α) and beta interferon (IFN-β)), protein levels of heat shock proteins (HSPs), levels of malondialdehyde (MDA), activities of glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD), and histopathological changes of spleens were detected on the 20th, 40th, and 60th day. 29032405 2018
CUI: C0025202
Disease: melanoma
melanoma
0.030 AlteredExpression disease BEFREE Further mechanistic analysis showed that TRIP4 promoted melanoma growth through modulation of COX-2 and iNOS expression partially by activating NF-κB signaling indirectly and partially by the direct anchoring of itself at COX-2 and iNOS promoter via synergy with p300. 28899685 2018
CUI: C0025202
Disease: melanoma
melanoma
0.030 AlteredExpression disease BEFREE NS3 mutants lacking the helicase domain retained the ability to control virus signaling initiated by retinoic acid-inducible gene-I (RIG-I) or melanoma differentiation antigen 5 and suppressed the downstream activation of interferon regulatory factor-3 (IRF-3) and nuclear factor kappaB (NF-kappaB) through the targeted proteolysis of IPS-1. 17289677 2007
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.030 GeneticVariation disease BEFREE Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study. 12490535 2003
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.030 GeneticVariation disease BEFREE No association between Parkinson's disease and three polymorphisms in the eNOS, nNOS, and iNOS genes. 17174475 2007
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.030 AlteredExpression disease BEFREE Consistent with these in vitro findings, blocking mGlu<sub>5</sub> attenuated the anti-inflammatory effects of T10 in an LPS-induced PD model and blocked the decreases in the number and morphology of ionized calcium binding adaptor molecule 1-positive microglia and LPS-induced iNOS protein expression caused by T10 treatment. 29649522 2018
Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site
0.030 AlteredExpression disease BEFREE A significant increase of iNOS gene expression was observed in nasopharyngeal exudate cells obtained from infants during the acute phase of RSV bronchiolitis. 10410996 1999
Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site
0.030 AlteredExpression disease BEFREE Experiments with bone marrow chimeras indicated that RSV-induced lung pathology was most severe when IPS-1 expression was lacking in both immune and nonimmune cell populations. 23136205 2012
Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site
0.030 AlteredExpression disease BEFREE Thus, both UTP- and iNOS-generated reactive species contribute to ENaC down-regulation in RSV-infected airway epithelial cells. 19131335 2009
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.030 AlteredExpression disease BEFREE Quantitation of iNOS transcripts and iNOS enzyme activity in non-cancerous mucosa of gastric cancer patients revealed a significant increase in iNOS transcripts and iNOS activity only in the mucosa of patients with stomach cancer of the intestinal type but not in the diffuse type. 14760971 2003
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.030 GeneticVariation disease BEFREE Rafiei et al recently described an association between the presence of the C150T polymorphism of the inducible nitric oxide synthase (iNOS) gene and Helicobacter pylori (H. pylori) induced gastric cancer. 23372371 2013
CUI: C0699791
Disease: Stomach Carcinoma
Stomach Carcinoma
0.030 GeneticVariation disease BEFREE A CT or TT polymorphism at position 150 in the iNOS gene significantly increases the risk of GC and may be a marker for GC susceptibility. 23002365 2012
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease
0.030 GeneticVariation disease BEFREE A functional variant of the iNOS gene flanking region is associated with LAD coronary artery disease: an autopsy study. 14636285 2003
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease
0.030 Biomarker disease BEFREE Sixty-four bovine teeth were prepared for full crown restoration (7.0±0.5 mm in height, 8.0 mm in cervical diameter, and 4.2 mm in incisal diameter) and were divided into two groups: CAD/CAM automation technology, IPS e.max CAD (CAD), and isostatic injection by heat technology, IPS e.max Press (PRESS). 27802123 2018
CUI: C1956346
Disease: Coronary Artery Disease
Coronary Artery Disease
0.030 Biomarker disease BEFREE Comparing initial K<sub>Ic</sub> values, lithium disilicate ceramic IPS e.max CAD showed significantly the highest and leucite-reinforced ceramic IPS Empress CAD significantly the lowest K<sub>Ic</sub> values (<i>p</i><0.001). 30849010 2019